Table 2.
PEEP trials in early COVID-19 ARDS patients.
| Patient: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | Mean | SD | Median | Inter-quartile range |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FiO2 prior-intubation | 1 | 0·7 | 0·8 | 0·7 | 0·75 | 0·7 | 0·8 | 0·8 | 0·1 | 0·75 | 0·1 |
| Initial PEEP at start of PEEP trial (mbar) | 24 | 13 | 24 | 18 | 20 | 18 | 24 | 20·1 | 3·9 | 20·0 | 6·0 |
| Results PEEP Trials: | |||||||||||
| Optimal PEEP (mbar) | 22.0 | 11.0 | 20.0 | 18.0 | 16.0 | 16.0 | 22.0 | 17·9 | 3·6 | 18·0 | 5·0 |
| VT (ml/ kg) | 6·3 | 6·1 | 7·0 | 6·7 | 5·5 | 7·2 | 6·4 | 6·4 | 0·5 | 6·4 | 0·53 |
| Respiratory rate (min−1) | 13.0 | 15.0 | 13.0 | 15.0 | 22.0 | 16.0 | 16.0 | 15·7 | 2·8 | 15·0 | 2·0 |
| Respiratory system compliance (CRS) (ml/cmH2O) | 59·6 | 45·0 | 79.0 | 64·8 | 30.0 | 41·9 | 60·1 | 54·3 | 15·2 | 59·6 | 19·0 |
| Driving pressure (ΔP) (mbar) | 8.0 | 9.0 | 7.0 | 11.0 | 17·2 | 11.0 | 9.0 | 10·3 | 3·1 | 9·0 | 2·5 |
| Trans-pulmonary driving pressure (ΔTP) (mbar) | 6·9 | 7·9 | 4·5 | 7·1 | 11·8 | 8·4 | 6·1 | 7·5 | 2·1 | 7·1 | 1·65 |
| End-expiratory trans-pulmon-ary pressure (TPexp) (mbar) | 3·1 | 0·3 | 0·8 | 10.0 | 10·8 | 2·6 | 7·9 | 5·1 | 4·1 | 3·1 | 7·25 |
| FiO2 | 0·5 | 0·4 | 0·3 | 0·35 | 0·5 | 0·6 | 0·35 | 0·4 | 0·1 | 0·4 | 0·15 |
| PaO2 (mmHg) | 85.0 | 85·0 | 71·0 | 65·3 | 81·7 | 79·6 | 88·7 | 79·5 | 7·8 | 81·7 | 9·7 |
| PaCO2 (mmHg) | 59.0 | 44·0 | 50·0 | 47·3 | 73·4 | 45·0 | 48·4 | 52·4 | 9·7 | 48·4 | 8·35 |
| PaO2/FiO2 ratio (mmHg) | 170·0 | 242·9 | 236·7 | 186·6 | 163·4 | 132·7 | 253·4 | 197·9 | 43·0 | 186·6 | 78·35 |
Results of PEEP trial shows the optimal PEEP as determined by decremental PEEP trial, and corresponding respiratory system mechanics and arterial blood gas analyses for all seven patients, as well as means, standard deviations (SD), median, and interquartile range.